Insulin Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Insulin stocks.

Insulin Stocks Recent News

Date Stock Title
Jul 5 PODD (PODD) - Analyzing Insulet's Short Interest
Jul 5 JNJ What's Going On With Johnson and Johnson Shares Friday?
Jul 5 JNJ J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
Jul 4 JNJ 3 High-Yield Dividend Stocks/ETFs to Buy Hand Over Fist in July
Jul 3 JNJ Johnson & Johnson receives Canadian approval for Rybrevant in first-line NSCLC
Jul 3 JNJ Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching In The Right Direction
Jul 3 JNJ Johnson & Johnson: Put Selling Can Yield A Potential 9.8% Return
Jul 3 MDT Health Care Stocks With A Long History Of Dividend Growth And Solid Yields
Jul 3 JNJ How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin
Jul 3 JNJ Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Jul 3 JNJ Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit
Jul 3 JNJ Johnson & Johnson gains FDA and EC approvals for TB treatment
Jul 3 JNJ Johnson & Johnson reports data from Phase III multiple myeloma treatment trial
Jul 2 MDT Medtronic stock closes in green and snaps a six-day losing streak
Jul 2 MDT Medtronic Loses 5% in a Month: What's Next for MDT Investors?
Jul 2 JNJ Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
Jul 2 JNJ Court Rules Against Johnson & Johnson In Talcum Powder Cancer Study Case
Jul 2 JNJ J&J says Carvykti beat standard drugs in late-stage blood cancer trial
Jul 2 JNJ CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
Jul 1 JNJ 5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Insulin

Insulin (from Latin insula, island) is a peptide hormone produced by beta cells of the pancreatic islets; it is considered to be the main anabolic hormone of the body. It regulates the metabolism of carbohydrates, fats and protein by promoting the absorption of carbohydrates, especially glucose from the blood into liver, fat and skeletal muscle cells. In these tissues the absorbed glucose is converted into either glycogen via glycogenesis or fats (triglycerides) via lipogenesis, or, in the case of the liver, into both. Glucose production and secretion by the liver is strongly inhibited by high concentrations of insulin in the blood. Circulating insulin also affects the synthesis of proteins in a wide variety of tissues. It is therefore an anabolic hormone, promoting the conversion of small molecules in the blood into large molecules inside the cells. Low insulin levels in the blood have the opposite effect by promoting widespread catabolism, especially of reserve body fat.
Beta cells are sensitive to glucose concentrations, also known as blood sugar levels. When the glucose level is high, the beta cells secrete insulin into the blood; when glucose levels are low, secretion of insulin is inhibited. Their neighboring alpha cells, by taking their cues from the beta cells, secrete glucagon into the blood in the opposite manner: increased secretion when blood glucose is low, and decreased secretion when glucose concentrations are high. Glucagon, through stimulating the liver to release glucose by glycogenolysis and gluconeogenesis, has the opposite effect of insulin. The secretion of insulin and glucagon into the blood in response to the blood glucose concentration is the primary mechanism of glucose homeostasis.If beta cells are destroyed by an autoimmune reaction, insulin can no longer be synthesized or be secreted into the blood. This results in type 1 diabetes mellitus, which is characterized by abnormally high blood glucose concentrations, and generalized body wasting. In type 2 diabetes mellitus the destruction of beta cells is less pronounced than in type 1 diabetes, and is not due to an autoimmune process. Instead there is an accumulation of amyloid in the pancreatic islets, which likely disrupts their anatomy and physiology. The pathogenesis of type 2 diabetes is not well understood but patients exhibit a reduced population of islet beta-cells, reduced secretory function of islet beta-cells that survive, and peripheral tissue insulin resistance. Type 2 diabetes is characterized by high rates of glucagon secretion into the blood which are unaffected by, and unresponsive to the concentration of glucose in the blood. Insulin is still secreted into the blood in response to the blood glucose. As a result, the insulin levels, even when the blood sugar level is normal, are much higher than they are in healthy persons.
The human insulin protein is composed of 51 amino acids, and has a molecular mass of 5808 Da. It is a dimer of an A-chain and a B-chain, which are linked together by disulfide bonds. Insulin's structure varies slightly between species of animals. Insulin from animal sources differs somewhat in effectiveness (in carbohydrate metabolism effects) from human insulin because of these variations. Porcine insulin is especially close to the human version, and was widely used to treat type 1 diabetics before human insulin could be produced in large quantities by recombinant DNA technologies.The crystal structure of insulin in the solid state was determined by Dorothy Hodgkin. It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.

Browse All Tags